Clinical Trial

Experimental Treatment for Gastrointestinal Inflammation

Study Description

Radiation Dose in Humans From Orally Administered Tc99m-Heparin

This is a research study of a new agent used for evaluation of inflammation in the GI tract. This agent is investigational and thus is being studied to determine appropriate dosing and administration in both normal controls (i.e. people without gastrointestinal complaints) and patients with eosinophilic disease (i.e. those with an immune reaction and inflammation in their bodies with a certain cell called an eosinophil). The study will test whether the radiolabeled agent will bind to the inflammation of eosinophilic esophagitis patients because an animal model of eosinophilic esophagitis which shows the striking deposition of eosinophil granule proteins is not available.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Radiation - Computerized Tomography scan

imaging scan from a person's eyes to their thighs

Radiation - Single Photon Emission Computed Tomography scans

imaging scan taken during, and after, the administration of the radioactive agent

Drug - Technetium Tc 99M

subjects are administered radioactive heparin as part of study participation.

Radiation - Planar Images

2 dimensional imaging - whole body planar scans

Procedure - Esophagogastroduodenoscopy

esophagogastroduodenoscopy with tissue biopsies

Additional Information

Official Study Title

Radiation Dose in Humans From Orally Administered Tc99m-Heparin

Clinical Trial ID

NCT04069429

ParticipAid ID

b2kBNd